The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Targeting GPC3 in HCC: bsAbs, ADCs and CAR-T
Hong Jae Chon, MD, PhD, CHA University, Seongnam, South Korea, discusses the various investigational approaches for targeting GPC3 in hepatocellular carcinoma (HCC), including CAR T-cell therapies, antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs). Dr Chan highlights the potential of BGB-2033 as a practical treatment option with promising anti-tumor activity and a favorable safety profile, and notes that it is being evaluated as monotherapy in later-line settings and in combination strategies for earlier lines of treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
